Compare VanEck Gold Miners ETF (GDX) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Gold Miners ETF vs Pfizer Inc — how do they compare? VanEck Gold Miners ETF trades at $88.8 (market cap $25.65B), while Pfizer Inc trades at $27.78 (market cap $159.59B). The key difference: Pfizer Inc is far larger — about 6.2× VanEck Gold Miners ETF's market cap, and Pfizer Inc pays a 6.14% dividend while VanEck Gold Miners ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Gold Miners ETF for 76 Days and Pfizer Inc for 158 Days on average.
| GDX | PFE | |
|---|---|---|
Market Cap | $25.65B | $159.59B |
Volume | 20,709,928 | 30,937,010 |
52-Week High | $115.84 | $29.02 |
52-Week Low | $68.28 | $23.67 |
Typical Hold Time | 76 Days | 158 Days |
Sector | — | Health |
Enterprise Value | — | $211.09B |
Dividend Yield | — | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDX trades at $85.46, down 3.13% today amid a bearish technical signal with 13 of 13 moving averages indicating sell signals. The ETF faces pressure from rising interest rates impacting dividend stocks and metals, with silver's sharp decline highlighting sector weakness. Recent news notes institutional selling by Allworth Financial and HB Wealth Management, though Ameritas Advisory increased its stake. Support sits at $84-$85, with resistance at $86-$87.
The outlook remains cautious due to bearish technicals and macro headwinds, but some analysts see value in gold miners' low valuations. Key risks include interest rate sensitivity and metals volatility, while potential catalysts include gold price stability and institutional accumulation. Investors should weigh technical weakness against long-term diversification benefits.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Gold Miners ETF
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
